MedTrace Logo

APC8015 and Bevacizumab in Treating Patients With Prostate Cancer

NCT00027599 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2013-02-11

No results posted yet for this study

Summary

Phase II trial to study the effectiveness of APC8015 combined with bevacizumab in treating patients who have undergone radiation therapy and/or surgery and who have progressive prostate cancer. Biological therapies such as APC8015 use different ways to stimulate the immune system and stop cancer cells from growing. Monoclonal antibodies such as bevacizumab can locate tumor cells and kill them without harming normal cells. Combining monoclonal antibody therapy with biological therapy may kill more cancer cells.

Conditions

Interventions

BIOLOGICAL

bevacizumab

BIOLOGICAL

prostatic acid phosphatase-sargramostim fusion protein

BIOLOGICAL

sipuleucel-T

BIOLOGICAL

therapeutic autologous dendritic cells

PROCEDURE

in vitro-treated peripheral blood stem cell transplantation

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Eric J. Small, MD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-12-31
Primary Completion
2007-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00027599 on ClinicalTrials.gov